June 16, 2020 / 3:29 PM / 21 days ago

Factbox: AstraZeneca's potential coronavirus vaccine

(Reuters) - British drugmaker AstraZeneca’s latest agreement to manufacture its potential COVID-19 vaccine, with Cobra Biologics, aims for first delivery of the candidate shot to the UK in September.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

It is one of many treatments being tested around the world as drugmakers race to combat the pandemic that has killed more than 431,000 globally. There are currently no approved treatments or vaccines for COVID-19.

For a FACTBOX on vaccines and treatments, click here:

Here are the main details about the experimental vaccine and AstraZeneca’s steps so far to agree supply and production deals:


It was developed by the University of Oxford and licensed to AstraZeneca, and is a recombinant viral vector vaccine. It uses a weakened version of the common-cold virus spiked with proteins from the novel coronavirus to build immunity.


Likely to provide protection against contracting COVID-19 for about a year.


The shot, AZD1222, would cost about 2.5 euros ($2.8) per dose in Europe, according to Italy’s health ministry, and the company does not expect to profit from it during the pandemic. The costs in other regions have not been disclosed.


Currently in late-stage clinical trials in humans in Britain. Brazil and the United States have also approved trials. (bit.ly/3hA8T03)


First indication on efficacy would likely come in June or July.

Data from studies is expected by August to September.

Delivery of first dose expected between September and October.

Experts predict a safe and effective vaccine could take 12-18 months to develop.


Currently at 2.1 billion

Reporting by Pushkala Aripaka in Bengaluru; editing by Josephine Mason and Susan Fenton

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below